title: ACR Appropriateness Criteria® on cerebrovascular disease.
abstract: Stroke is the sudden onset of focal neurologic symptoms due to ischemia or hemorrhage in the brain. Current FDA-approved clinical treatment of acute ischemic stroke involves the use of the intravenous thrombolytic agent recombinant tissue plasminogen activator given <3 hours after symptom onset, following the exclusion of intracerebral hemorrhage by a noncontrast CT scan. Advanced MRI, CT, and other techniques may confirm the stroke diagnosis and subtype, demonstrate lesion location, identify vascular occlusion, and guide other management decisions but, within the first 3 hours after ictus, should not delay or be used to withhold recombinant tissue plasminogen activator therapy after the exclusion of acute hemorrhage on noncontrast CT scans. MR diffusion-weighted imaging is highly sensitive and specific for acute cerebral ischemia and, when combined with perfusion-weighted imaging, may be used to identify potentially salvageable ischemic tissue, especially in the period >3 hours after symptom onset. Advanced CT perfusion methods improve sensitivity to acute ischemia and are increasingly used with CT angiography to evaluate acute stroke as a supplement to noncontrast CT. The ACR Appropriateness Criteria(®) are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
authors.affiliation: Columbia University Medical Center, New York, NY, USA. rld17@columbia.edu
authors.forename: Robert L
authors.initials: RL
authors.lastname: DeLaPaz
authors.forename: Franz J
authors.initials: FJ
authors.lastname: Wippold
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Cornelius
authors.forename: Sepideh
authors.initials: S
authors.lastname: Amin-Hanjani
authors.forename: Edgardo J
authors.initials: EJ
authors.lastname: Angtuaco
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Broderick
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Brown
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Creasy
authors.forename: Patricia C
authors.initials: PC
authors.lastname: Davis
authors.forename: Charles F
authors.initials: CF
authors.lastname: Garvin
authors.forename: Brian L
authors.initials: BL
authors.lastname: Hoh
authors.forename: Charles T
authors.initials: CT
authors.lastname: McConnell
authors.forename: Laszlo L
authors.initials: LL
authors.lastname: Mechtler
authors.forename: David J
authors.initials: DJ
authors.lastname: Seidenwurm
authors.forename: James G
authors.initials: JG
authors.lastname: Smirniotopoulos
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Tobben
authors.forename: Alan D
authors.initials: AD
authors.lastname: Waxman
authors.forename: Greg J
authors.initials: GJ
authors.lastname: Zipfel
mesh_terms: D002561:Cerebrovascular Disorders / Q000175:diagnosis*; D006801:Humans; D008279:Magnetic Resonance Imaging; D017410:Practice Guidelines as Topic; D011829:Radiation Dosage; D011871:Radiology; D012955:Societies, Medical; D014057:Tomography, X-Ray Computed; D014481:United States